December 26, 2024 11:25 AM ESTUpdated December 26, 11:13 PM

WuXi AppTec will sell cell and gene therapy business to private equity firm

Max Bayer

Pharma Reporter

WuXi AppTec will sell its Advanced Therapies unit to the US private equity firm Altaris for an undisclosed amount, a long-anticipated move after months of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

WuXi AppTec will sell cell and gene therapy business to private equity firm

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Updated: Novartis claims best earnings in years, validating shift to pure-play strategy

AbbVie executives bask in Skyrizi, Rinvoq successes as the drugs take up Humira's mantle

Daiichi Sankyo taps new CEO, aims to build up ADC franchise

Vertex's non-opioid pain drug is approved by FDA, bringing first of new class to market

Roche separates CFO, informatics posts; Lilly execs land at Kailera, Neurocrine

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Pharma Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

WuXi AppTec will sell cell and gene therapy business to private equity firm